An FDA panel has backed the safety and efficacy of Johnson & Johnson's bedaquiline drug for tuberculosis, but also pointed out possible heart and liver-safety issues. The drug works by targeting the adenosine triphosphate synthase enzyme, which the pathogen requires to generate energy.